Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1992-6-16
|
| pubmed:abstractText |
Defects in the interleukin-2 (IL-2)-mediated T-lymphocyte activation/proliferation pathway have been implicated as contributing to the compromised immune function observed in patients following bone marrow transplantation (BMT). Since interleukin-4 (IL-4) is also involved in T-lymphocyte function, we have examined whether phytohemagglutinin (PHA)- or anti-CD3 (OKT3)-activated lymphocytes obtained from patients after allogeneic or autologous BMT are capable of proliferating in response to human recombinant IL-4, and compared these results to those obtained using human recombinant IL-2. Peripheral blood lymphocytes from marrow graft recipients were initially cultured for 3 days in the presence of PHA or OKT3. Such mitogen-activated lymphocytes exhibited little or no proliferation (as assessed by incorporation of [3H]-thymidine) following culture for an additional 3 days in the presence of IL-4 or IL-2. Results were similar for lymphocytes obtained from patients early (less than 4 months) after marrow grafting and those obtained from long-term marrow graft recipients with chronic graft-vs-host disease at the time of testing. In contrast, lymphocytes obtained from healthy individuals proliferated in response to IL-4, as well as to IL-2, following initial activation with PHA or OKT3. Immunofluorescence analysis showed that in normals equal numbers of CD4 and CD8 cells proliferated after stimulation with anti-CD3 antibody and IL-2. However, in BMT patients there was a predominant proliferation of CD8 cells using the same stimulator. These results indicate that defects in the IL-4-mediated T-lymphocyte activation/proliferation pathway may also contribute to the immunodeficiency observed following BMT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1148-5493
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
131-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1813016-Adolescent,
pubmed-meshheading:1813016-Adult,
pubmed-meshheading:1813016-Bone Marrow Transplantation,
pubmed-meshheading:1813016-Cell Division,
pubmed-meshheading:1813016-Female,
pubmed-meshheading:1813016-Humans,
pubmed-meshheading:1813016-Immunologic Deficiency Syndromes,
pubmed-meshheading:1813016-Interleukin-2,
pubmed-meshheading:1813016-Interleukin-4,
pubmed-meshheading:1813016-Leukemia,
pubmed-meshheading:1813016-Lymphocyte Activation,
pubmed-meshheading:1813016-Lymphocyte Subsets,
pubmed-meshheading:1813016-Lymphoma,
pubmed-meshheading:1813016-Male,
pubmed-meshheading:1813016-Middle Aged,
pubmed-meshheading:1813016-Mitogens,
pubmed-meshheading:1813016-Multiple Myeloma,
pubmed-meshheading:1813016-Myelodysplastic Syndromes,
pubmed-meshheading:1813016-Transplantation, Autologous,
pubmed-meshheading:1813016-Transplantation, Homologous
|
| pubmed:articleTitle |
Proliferation of peripheral lymphocytes to interleukin-2 and interleukin-4 after marrow transplantation.
|
| pubmed:affiliation |
Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, Canada.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|